Search Videos and More
Symposium
The Young-Onset Colorectal Cancer Center’s Gut Instincts Series
The Young-Onset Colorectal Cancer Center’s Gut Instincts Series is a quarterly webinar for healthcare professionals to learn more about colorectal cancer and the unique challenges individuals diagnosed under the age of 50 face. Events are hosted by Young-Onset Colorectal Cancer Center Director Dr. Kimmie Ng and include a panel of medical experts and a patient perspective.
News
Dana-Farber Researchers Launch New Project to Investigate How Neighborhoods Contribute to Prostate Cancer Inequity
Researchers at Dana-Farber Cancer Institute and the Rutgers University Cancer Institute are investigating what it is about neighborhoods that may increase a Black man’s risk of dying from prostate cancer.
News
FDA Approves New Treatment Option For Glioma
The U.S. Food and Drug Administration’s accelerated approval of a two-drug therapy for solid tumors carrying a specific mutation in the BRAF gene is a prime example of this trend. For patients with glioma brain cancer that harbors the mutation, the ruling is a landmark.
News
Study Shows That Genomic Tumor Profiling of Pediatric Tumors Can Enhance Clinical Care
Results of a study of molecular tumor profiling in young patients revealed a high rate of genetic alterations with potential for impacting clinical care, including clarifying diagnoses and treatment with matched, precision cancer drugs.
News
Study Finds Breast Cancers with Low Levels of HER2 Protein Are Not a Distinct Subtype of the Disease
When researchers discovered that breast cancers with lower levels of HER2 often respond to a trastuzumab-and-chemotherapy drug conjugate, they wondered whether such tumors represent a distinct subtype of breast cancer, with its own unique behavior and prognosis.
Symposium
ASCO 2022 Highlights
Below please find highlights of key advances in cancer research and an overview of Dana-Farber faculty presentations at ASCO.
News
Dana-Farber/Boston Children's Again Named Top Pediatric Cancer Program
U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center #1 in the nation in its 2022-23 Best Children's Hospitals report. Dana-Farber/Boston Children's has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking's inception, earning more #1 rankings than any other program.
News
Improved Progression-Free Survival in Patients with Multiple Myeloma Following Three-Drug Therapy with Autologous Stem Cell Transplant
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
News
Targeted Drug Achieves 43% Response Rate in KRAS-Mutated Lung Cancer
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.
Symposium
Lymphoma and Chronic Lymphocytic Leukemia: Updates in Management
This course addresses the rapidly changing landscape in the management and treatment of non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.
News
Race, Ethnicity, and Poverty Linked to Worse Outcomes in Children Treated for High-Risk Neuroblastoma
Children with high-risk neuroblastoma had worse outcomes if they were from certain racial/ethnic groups or were on public rather than private insurance, despite being treated in clinical trials with standardized protocols, according to a study led by investigators from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
News
Combination Therapy Produces Encouraging Results in Patients with Gynecologic Cancers with Distinct Genetic Mutations
A two-drug therapy that sets certain cancer cells up for failure and then finishes them off showed encouraging activity in a clinical trial of patients with gynecologic cancers that harbor mutations in a key gene, Dana-Farber investigators reported at the Society for Gynecologic Oncology (SGO) Annual Meeting in March.